![]() ![]() Dyslipidemia, characterized as increased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and/or decreased high-density lipoprotein (HDL) levels in the serum, is prevalent in SLE patients with an incidence ranging between 18.1% and 75%. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production in women of childbearing age. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: The authors have declared that no competing interests exist. ![]() This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper.įunding: This study was supported by Nanjing Medical Science and Technique Development Foundation (Z.C., ZKX16039). Received: DecemAccepted: MaPublished: April 16, 2020Ĭopyright: © 2020 Zhang et al. PLoS ONE 15(4):Įditor: Deyu Fang, Northwestern University Feinberg School of Medicine, UNITED STATES (2020) Clinical significance of non-thyroidal illness syndrome on disease activity and dyslipidemia in patients with SLE. Further studies are needed to confirm these preliminary observations.Citation: Zhang X, Liu L, Ma X, Hu W, Xu X, Huang S, et al. These preliminary data suggest a possible role of Irisin in modulation of antioxidant systems in two chronic syndromes characterized by low T3 syndrome, but with differential pattern in the two models studied. Irisin was significantly higher in Group B vs A and controls (Mean ± SEM: 20.18 ± 0.61 ng/ml vs 2.77 ± 0.77 and 13.06 ± 0.56, respectively P<0.05) a significant correlation between Irisin and TAC was observed only in group B. Irisin has been evaluated by ELISA method and Total Antioxidant (TAC) capacity by spectrophotometric method. Group A included Chronic heart failure patients ( n=18 Aged 70.22 ± 2.78 ys BMI ± 27.75 ± 1.28 Kg/m 2) Group B included Chronic Kideny Disease patients ( n=29 Aged 67.03 ± 2.64 BMI 24.53 ± 1.01) Finally, 11 normal subjects have been assumed as controls. Therefore, we performed a case-control study with the primary end-point to evaluate Irisin levels in two models of NTIS, such as chronic heart failure and chronic kidney disease during haemodialytic treatment the secondary end-point was the correlation with total antioxidant capacity in order to establish a possible role of Irisin in the modulation of antioxidant systems. Unconclusive data have been reported about the role of Irisin in chronic diseases such as chronic heart and renal failure moreover, no correlation between Irisin and antioxidant status has been investigated. Muscle is one of the main targets of thyroid hormone on the other hand, Irisin is a novel discovered myokine firstly identified for its ability to induce browning of white adipose tissue, increase energy expenditure and finally protect against insulin resistance. Moreover there is a tissue-specific thyroid hormone transport, receptor binding and hormone metabolism. ![]() However oxidative stress is linked to NTIS in a vicious circle, due to deiodinases alteration and negative effects of low T3 on antioxidant levels or activity. Non-thyroidal-illness syndrome (NTIS) is present in chronic diseases and considered an adaptive mechanism.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |